Opendata, web and dolomites

FACTs

Fast Acting Virus Control Strategies for Production Animal Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FACTs project word cloud

Explore the words cloud of the FACTs project. It provides you a very rough idea of what is the project "FACTs" about.

vaccines    unable    brazil    disease    labour    shedding    beef    contracts    separated    markets    time    alone    infect    prevent    feed    bovine    administered    return    maximize    business    disruptive    industry    million    company    persistently    utero    billions    detect    refinement    investors    globally    finalized    added    treatment    difficult    until    producing    supportive    arrival    massive    150    diarrhoea    clinical    decreased    antigenic    feedlot    belgian    leaders    calves    rapid    kols    endemic    efficiency    pi    expressed    consult    assist    house    successful    sign    peak    ing    initially    cattle    immune    minimize    investment    virovet    facts    continuous    regulatory    trl    drug    susceptibility    introduction    euros    animals    vaccination    costing    sheet    signed    conduct    opinion    inadequate    infected    biotech    shed    contamination    variability    exposed    introducing    secondary    host    stage    sales    infection    mortality    virus    conventional    herd    form    amounts    market    bvd    auction    plan    viral    predicted    standard    launched    reduce   

Project "FACTs" data sheet

The following table provides information about the project.

Coordinator
ARATANA THERAPEUTICS NV 

Organization address
address: AMBACHTENLAAN 1
city: HEVERLEE
postcode: 3001
website: www.okapi-sciences.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website http://www.virovet.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ARATANA THERAPEUTICS NV BE (HEVERLEE) coordinator 50˙000.00

Map

 Project objective

The objective of the FACTs project is to sign a term sheet with investors for ViroVet, an emerging Belgian biotech company, aimed at developing and introducing a disruptive treatment for bovine viral diarrhoea (BVD) in beef cattle. BVD is a globally endemic disease of cattle costing the industry billions of Euros every year in the form of increased mortality, decreased feed efficiency and increased susceptibility to secondary disease. Conventional BVD vaccines are unable to fully control the disease due to antigenic variability of the virus and inadequate host immune response to vaccination. BVD virus can infect calves in utero leading to persistently infected (PI) animals that are difficult to detect but that shed massive amounts of virus, resulting in continuous contamination of the herd. The product will initially be launched in the EU and US, with other large beef-producing markets, such as Brazil, also considered. It will be administered to cattle upon arrival at the feedlot or auction house, which is a time of high susceptibility to infection. The drug will prevent exposed animals from developing clinical disease and will reduce viral shedding by PI animals until they are identified and separated from the herd. The drug will be added to standard processing procedures to minimize labour time and cost. The BVD project is in TRL-6 stage and is predicted to reach market in 6-8 years’ time with peak sales of €150 million in the EU and US alone. Key opinion leaders (KOLs) are supportive of the product and a number of investors have expressed their interest. In Phase I, ViroVet will conduct market research and consult with KOLs in Europe and in other major beef markets to ensure successful introduction of the product. A comparative analysis of regulatory requirements will assist in the refinement of the business plan that will minimize time to market and maximize rapid return on investment. Contracts with investors will be finalized and a term sheet will be signed.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FACTS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FACTS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More